title: Two hyperandrogenic adolescent girls with congenital portosystemic shunt.
abstract: We describe two adolescent girls with a congenital portosystemic shunt who exhibited hyperandrogenism in addition to insulin resistant hyperinsulinaemia. Case 1 was referred to our clinic to undergo a routine clinical work-up prior to tonsillectomy at 14 years of age. Mild liver dysfunction was identified and hypogenesis of the portal vein with a congenital portosystemic shunt diagnosed. Primary amenorrhoea and virilization were evident and an endocrinological evaluation revealed hyperandrogenism and insulin resistant hyperinsulinaemia. Case 2 was referred at 15 years of age because of cardiomegaly. Mild liver dysfunction and hyperbilirubinaemia led to a diagnosis of agenesis of the portal vein with a congenital portosystemic shunt. Virilization was evident and an endocrinological evaluation revealed hyperandrogenism and insulin resistant hyperinsulinaemia. The haemodynamics of these patients were similar to those of secondary portosystemic shunt due to liver cirrhosis, which is often associated with hyperinsulinaemia and/or non-insulin dependent diabetes mellitus. On the other hand, hyperandrogenism is associated with certain insulin-resistant conditions with hyperinsulinaemia, including the polycystic ovary syndrome (PCO). Hyperinsulinaemia is believed to cause hyperandrogenism in patients with PCO by stimulating androgen production in both the ovary and adrenal gland. Therefore, in congenital portosystemic shunts, hyperinsulinaemia is also thought to cause hyperandrogenism due to the same mechanism.
  
  
  CONCLUSIONS
  A certain percentage of female patients with hyperandrogenism, likely including those with polycystic ovary syndrome may also have congenital portosystemic shunts. Our results indicate that serum levels of total bile acids and ammonia are prognostic indicators of this hepatic vascular anomaly.
authors.affiliation: First Department of Paediatrics, Toho University School of Medicine, Tokyo, Japan. ped1adm@med.toho-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Satoh
authors.forename: S
authors.initials: S
authors.lastname: Yokoya
authors.forename: Y
authors.initials: Y
authors.lastname: Hachiya
authors.forename: M
authors.initials: M
authors.lastname: Hachiya
authors.forename: T
authors.initials: T
authors.lastname: Fujisawa
authors.forename: K
authors.initials: K
authors.lastname: Hoshino
authors.forename: T
authors.initials: T
authors.lastname: Saji
mesh_terms: D000293:Adolescent; D000324:Adrenocorticotropic Hormone; D000735:Androstenedione / Q000097:blood; D003687:Dehydroepiandrosterone / Q000097:blood; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D017588:Hyperandrogenism / Q000097:blood / Q000150:complications* / Q000473:pathology; D006946:Hyperinsulinism / Q000097:blood / Q000150:complications; D007333:Insulin Resistance; D018810:Magnetic Resonance Angiography; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000150:complications; D011169:Portal Vein / Q000002:abnormalities*; D014682:Vena Cava, Inferior / Q000002:abnormalities*
chemical_list: D000735:Androstenedione; D003687:Dehydroepiandrosterone; D000324:Adrenocorticotropic Hormone